Draft Rules to substitute existing Schedule M to bring in GMP on par with international standards
SW DESHPANDE, FORMER JOINT COMMISSIONER, FDA MAHARASHTRA AND ADVOCATE FOUNDER, PHARMALEX
In my opinion, the Drugs and Cosmetics Act is well-drafted and has been amended from time to time with major changes in 1982 and 2008. Rules have a number of amendments and Good Manufacturing Practices are upgraded by amending Schedule M and Medical Devices Rules 2017. New Drugs and Clinical Trials Rules 2019 have been incorporated. Draft Rules will substitute existing Schedule M to bring in Good Manufacturing Practices (GMP) on par with international standards. Major industry stakeholders want many changes in the draft rules as it is apprehended that it will require huge investment leading to an increase in prices. Medium and small scale industry is likely to be affected most. It has become a fashion to criticise Acts enacted in the pre-independence era.
There is a need for a revised drug classification system
DR VARUN GUPTA, CONVENOR, DIGITAL HEALTH PLATFORMS
India has made big strides on the World Bank’s ease of doing business index and Prime Minister Narendra Modi's vision of minimum government and maximum governance. It is commendable but there is an urgent requirement to remove/amend obsolete regulations that have outlived their utility and hamper governance by creating avoidable confusion. There are many sections in the Drugs & Cosmetics Act and Rules 1940 & 1945 which needs to be identified on priority. One of them is the current classification of medicines.
Current classification of medicines in India under the Drugs and Cosmetics Act into Schedule G, H, H1, X is outdated, evolved through patchwork over the years, and needs to be thoroughly updated. The primary aim of the scheduling system is to ensure appropriate access to medicines while balancing public health and safety. There is a need for a revised drug classification system that is more comprehensive in coverage and eliminates the overlaps between classes and addresses implementation challenges in the diverse and fragmented ecosystem in India.
Accessibility, affordability, and lack of transparency are the major challenges in the sector of sale of medicines. These barriers could be effectively overcome by adopting technology, specifically the internet, into the healthcare system. In addition, it provides tracking and traceability of medicines, abuse prevention, addressing the consumption of drugs without prescription, tax loss, and value-added services for consumer empowerment in healthcare. Moreover, it will foster entrepreneurship, innovation, attract foreign direct investment, and create jobs. These are all key areas of national development.
The CDSCO should enforce all drug-related laws throughout the country
ASHOKSWAMY HEROOR, PRESIDENT, KARNATAKA STATE REGISTERED PHARMACISTS ORGANISATION
The following areas may be considered before redrafting the Drugs and Cosmetics Act and Rules.
Enforcement of the act
Present scenario: Partly enforced by the Central Government and partly by State Governments.
Result: Uneven enforcement of the rules by the States. The industry grows in some encouraging States only. Clandestine activities in some States with the connivance of officers affect the entire nation.
Suggestion: The CDSCO should enforce all drug-related laws throughout the country.
Manufacturing Licensing Policy
Present scenario: Loan licenses, third-party arrangements, manufacturing and marketing arrangements, lending of trade names, etc., are being resorted to.
Result: Actual manufacturer suffers in the sales. Substandard, not of standard quality, cheap products, unhygienic preparations flood the market. The government is cheated by avoiding taxes by the tricks played by large manufacturers. Helps them in the money laundering business and to amass black money.
Suggestions: All such unprincipled practices should be banned. Natural justice
Present scenario: Only some reputed firms maintain cold chains in distribution.
Suggestions: Even small scale manufacturers and loan licencees should follow it strictly.
Competent Technical Staff
Present scenario: All science graduates are eligible to become CTS.
Results: Professional pharmacy graduates are unemployed. Quality cannot be built into drugs.
Suggestion: Only pharmacy graduates registered in the pharmacy council, should become CTS for manufacturing and testing. 18-months experience also should be waived. D.Pharm should be approved for quality control CTS as they are more technical than BScs.
Any change should be phased out over a span of a few years while harmonising the ICH framework
MANIKANDAN RAMALINGAM,VP- R&D, GRANULES INDIA
While the industry is undergoing a paradigm shift towards quality-driven procedures, it is good to see that the national regulators have decided to reframe the guidance. The key focus for the revision should be on harmonization of quality practices, GMP/GLP requirements, safety, and efficacy that would directly benefit the patient population with high-quality medicines. Focusing on these key areas in the upcoming revisions should bridge the gap between the Indian Drugs and Cosmetics Act 1940 and global regulatory standards (ICH, WHO, US-FDA, and other regulatory guidance). However, this shift in practice would have a significant implication on the cost dynamics of the product.
Any change should be phased out over a span of a few years, harmonizing the ICH framework first and then going into detailed execution to meet the quality standards of other regulated markets. Pharma manufacturers in the Indian market, supplying product to India should be given time to implement quality into systems in a cost-efficient manner. If implemented overnight there will be significant disruptions. On the commercial side, the government should also consider having different price ranges, ceilings, and floors for products depending on the therapeutic area of focus, availability and affordability.
Involve pharmacy academicians across the country in making a new law
Continue reading your story on the app
Continue reading your story in the magazine
We might need to redefine our approach to drug discovery and approval to be prepared for the future
Hitesh Windlass, MD,Windlas Biotech gives an overview of the changes bought by COVID-19 pandemic in the pharma industry, his organisation’s plans for future growth and more, in an interview with Lakshmpriya Nair
We help our customers create future-ready pharma manufacturing and biotech facilities
Sanjay Sudhakaran, VP, Digital Energy, Schneider Electric India expands on the value proposition of digital energy systems for the pharma sector, giving some examples of how companies achieved RoI on this investment, in an interaction with Viveka Roychowdhury
Virtual clinical trials would have a tremendous advantage in expanding the reach of clinical trials
Suneela Thatte, VP and Head - R&D Solutions India, IQVIA speaks on the challenges faced by CROs due to the pandemic, the subsequent learnings in clinical research/trials, emerging trends in this arena and more, in an interaction with Viveka Roychowdhury
Waters Corporation appoints Pearl S Huang to Board of Directors
She has significant scientific expertise in the discovery of biologics, small molecule and nucleic acid-based therapies, as well as in drug discovery and the development of clinical trials
Fighting counterfeiting requires a long-term battle and we need to start somewhere
Globally, incidents of fake, counterfeit pharma products are on the rise and recent cyber attacks on some pharma companies involved in the development of COVID-19 vaccines are raising further alarm. Nakul Pasricha, President, Authentication Solution Providers’ Association (ASPA) talks about the need for a phygital approach to secure supply chain integrity and facilitate easy identification of genuine COVID-19 vaccines, with Usha Sharma
FDI in brownfield pharma projects - Critical analysis
Arvind Sharma, Partner, Shardul Amarchand Mangaldas & Co informs that the extant regulatory regime for FDI in brownfield projects follows a balanced approach as it safeguards supplies for domestic consumption and ensures foreign investments as well as technological advancement for the pharma sector
Effective effluent management: Key to tackle AMR
Dr Jyoti Joshi, Head-South Asia,The Center for Disease Dynamics, Economics & Policy (CDDEP); Adjunct Professor,Amity Institute of Public Health emphasises that the government and the pharma industry need to establish strategic partnerships to address the issue of growing AMR due to pharma plant effluents
CIMS Medica organises Business Excellence Awards 2020
The award ceremony was held at the The Leela Palace Hotel, New Delhi to honour companies who contributed to the growth and development of the healthcare and pharma industry
BLUEPRINT FOR PROGRESS
Experts and veterans examine and explore strategies for India Pharma Inc to implement the lessons learnt from the COVID-19 pandemic as we enter a new year and a new decade
Reverse Brain Drain: Accelerated By Covid-19
Ankit Goyal, Healthcare and Lifesciences Leader India, Heidrick & Struggles finds that leadership hiring is attracting ‘returnee Indians’ in healthcare companies due to growing opportunities in India, and more recently, the impact of the pandemic
YOGA & PEACE
DEEPAK CHOPRA speaks with DAAJI about the role Yoga has to play in bringing about world peace. This is an excerpt from their conversation broadcast on International Day of Peace, September 21, 2020. That documentary is available at https://heartfulness.org/en/international-day-of-peace/.
Create the habit of meditation
CHIRAG KULKARNI, Co-Founder and CMO of Medly Pharmacies in the USA, speaks with RISHIKA SHARMA about creating a regular meditation practice, so as to make it a habit. He also shares how meditation has benefited both his personal and professional life.
SHIA'S PRIVATE TEMPLE OF DOOM!
Indiana Jones gig derailed by abuse scandal
"Food Raconteur” Ashok Nageshwaran wants to tell you a story.
THE MAKING OF A MODEL MINORITY
Indian Americans rarely stop to ask why our entrance into American society has been so rapid—or to consider what we have in common with other nonwhite Americans.
Business at Its Best
With a big hand from the government, pharmaceutical companies delivered the vaccine that the world desperately needed. Here’s how something in 2020 went right for a change
In 2017, DR. VANDANA SHIVA spoke with KIM HUGHES about the sacredness of the Earth, the work she has been doing to bring awareness and change in the field of sustainable agriculture, and the importance of understanding our interconnectedness with Nature, and how we can change the way we eat.
DIAMONDS - A Luxury Gem Steeped in Fact & Fable
The diamond is one fabled gemstone! For example, google “Hope Diamond” to see all the legends associated with just this one stone said to bring misfortune to its owners.
Brown Sugaa and Medusa
PHARMACEUTICAL SUPPLY CHAIN DISRUPTIONS DUE TO THE PANDEMIC
The COVID-19 pandemic is both a public health crisis and an economic disrupter too.